ALK and non-small cell lung carcinoma: This RNA-based nCounter codeset has been complemented with other clinical-relevant genes and is currently being used in the routine clinical context of our institution to detect specific fusion transcripts—7 ALK, 10 ROS1, 6 RET and 2 NTRK1—and METΔex14 mutations, giving significant good results in the context of molecular characterization of advanced NSCLC patients [27].